The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a
hormone receptor-positive
immunohistochemistry
progesterone receptor
prognosis
rapidly proliferating breast cancer
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
07
2019
accepted:
17
10
2019
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
epublish
Résumé
In the Italian Breast Cancer Intergroup Studies (IBIS) 3 phase III trial, we compared cyclophosphamide, methotrexate, 5-fluorouracil (CMF) alone to sequential epirubicin/CMF regimens in patients with rapidly proliferating early breast cancer (RPEBC). We performed a RPEBC was defined by thymidine labeling index (TLI) >3% or grade 3 or S-phase >10% or Ki67 >20%. We analyzed 466 patients with hormone-receptor-positive RPEBC receiving sequential epirubicin/CMF regimens followed by tamoxifen, and for whom the status of ER and PgR was available. Considering both cut-off values of 10% and 20%, PgR expression was significantly associated with age, menopausal status, and ER expression; HER2 status was associated with PgR status only at a cutoff value of 20% PgR. Upon univariate analysis, tumor size, nodal status, and PgR were significantly associated with disease-free survival (DFS) and overall survival (OS), while age class and local treatment type were associated only with DFS. Patients with PgR <20% showed lower 5- and 10-year DFS [hazard ratio (HR) = 1.48; 95%CI: 1.01-2.18; Our results highlight the independent prognostic relevance of PgR expression in patients with hormone-receptor-positive RPEBC treated with adjuvant chemotherapy and endocrine therapy, where the definition of prognostic subgroups is still a major need.
Sections du résumé
BACKGROUND
BACKGROUND
In the Italian Breast Cancer Intergroup Studies (IBIS) 3 phase III trial, we compared cyclophosphamide, methotrexate, 5-fluorouracil (CMF) alone to sequential epirubicin/CMF regimens in patients with rapidly proliferating early breast cancer (RPEBC). We performed a
METHODS
METHODS
RPEBC was defined by thymidine labeling index (TLI) >3% or grade 3 or S-phase >10% or Ki67 >20%. We analyzed 466 patients with hormone-receptor-positive RPEBC receiving sequential epirubicin/CMF regimens followed by tamoxifen, and for whom the status of ER and PgR was available.
RESULTS
RESULTS
Considering both cut-off values of 10% and 20%, PgR expression was significantly associated with age, menopausal status, and ER expression; HER2 status was associated with PgR status only at a cutoff value of 20% PgR. Upon univariate analysis, tumor size, nodal status, and PgR were significantly associated with disease-free survival (DFS) and overall survival (OS), while age class and local treatment type were associated only with DFS. Patients with PgR <20% showed lower 5- and 10-year DFS [hazard ratio (HR) = 1.48; 95%CI: 1.01-2.18;
CONCLUSIONS
CONCLUSIONS
Our results highlight the independent prognostic relevance of PgR expression in patients with hormone-receptor-positive RPEBC treated with adjuvant chemotherapy and endocrine therapy, where the definition of prognostic subgroups is still a major need.
Identifiants
pubmed: 32158505
doi: 10.1177/1758835919888999
pii: 10.1177_1758835919888999
pmc: PMC7047424
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835919888999Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
J Am Coll Surg. 2009 Mar;208(3):341-7
pubmed: 19317994
Clin Cancer Res. 2006 Aug 1;12(15):4614-8
pubmed: 16899609
Breast Cancer Res. 2014 Jun 20;16(3):R65
pubmed: 24951027
Breast Cancer Res Treat. 2014 Apr;144(2):307-18
pubmed: 24381054
Breast Cancer Res Treat. 2008 Mar;108(2):259-64
pubmed: 17530429
Breast Cancer Res Treat. 2015 Jul;152(1):57-65
pubmed: 26012644
J Clin Oncol. 2005 Oct 20;23(30):7721-35
pubmed: 16234531
Int J Cancer. 2009 Nov 1;125(9):2021-8
pubmed: 19588487
Oncologist. 2019 Feb;24(2):165-171
pubmed: 30171067
J Clin Oncol. 2003 May 15;21(10):1973-9
pubmed: 12743151
Br J Cancer. 2014 Feb 4;110(3):565-72
pubmed: 24300977
Clin Breast Cancer. 2017 Feb;17(1):41-47
pubmed: 27477822
World J Surg Oncol. 2015 Feb 07;13:33
pubmed: 25889186
J Clin Oncol. 2008 Mar 1;26(7):1059-65
pubmed: 18227529
Ann Oncol. 1993 Mar;4(3):213-9
pubmed: 8471553
J Clin Oncol. 2007 Sep 1;25(25):3846-52
pubmed: 17679725
Breast Cancer Res Treat. 2009 Mar;114(2):287-99
pubmed: 18425577
Clin Breast Cancer. 2015 Jun;15(3):204-11
pubmed: 25600243
Breast Cancer Res Treat. 2011 Feb;125(3):775-84
pubmed: 21132360
Ann Oncol. 2018 Oct 1;29(10):2153
pubmed: 29733336
J Clin Oncol. 2013 Jan 10;31(2):203-9
pubmed: 23233704
J Clin Oncol. 2010 Mar 1;28(7):1161-7
pubmed: 20124184
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s
pubmed: 15701879
Br J Cancer. 2017 Jul 11;117(2):e1
pubmed: 28399113
Breast Cancer Res Treat. 2016 Nov;160(2):313-322
pubmed: 27722840